Taiwanese Pharma Industry Analysed & Forecast in New Cutting-Edge GBI Research Report Available at MarketPublishers.com
11 Jun 2013 • by Natalie Aster
LONDON – Taiwan’s pharmaceutical market is expected to grow from USD 4.4bn in 2012 to reach USD 5.5bn by end-2018, growing at a CAGR of nearly 4% during 2012-2018. Despite its small size in comparison with other markets in the region, the Taiwanese pharmaceutical market could be a perfect entry point for start-ups as it offers the least resistance possible while opening the doors into larger markets at a later stage.
New cutting-edge report “Taiwan Pharmaceutical Market Outlook 2013” developed by GBI Research provides exhaustive analysis and forecast up to 2018 of the Taiwanese pharmaceutical marketplace.
The study reviews the political, economic and investment landscape in Taiwan; looks at the country’s healthcare system and infrastructure along with major health policy initiatives; examines the regulatory landscape. The research proceeds with a detailed market review, covering the market size and key segments, main therapeutic and emerging areas, drug distribution and pharmaceutical supply chain, as well as spending in pharma RnD. Details on the various market drivers and healthcare trends impacting growth in Taiwan’s pharmaceutical industry are provided as well. Additionally, the report profiles the leading biopharmaceutical companies, both domestic and overseas, operating in the country.
Companies discussed in the report include: Pfizer, Sanofi, Novartis, GlaxoSmithKline, The China Chemical & Pharmaceutical Company, Standard Chemicals & Pharmaceuticals Co. Ltd., Yung Shin Pharmaceutical. Ind. Co. Ltd., ScinoPharm Taiwan, and TTY Biopharm Company Limited.
Taiwan Pharmaceutical Market Outlook 2013
Published: June, 2013
Price: US$ 3,500.00
More new market reports by the publisher can be found at GBI Research page.